Skip to main navigation Skip to search Skip to main content

Physician perceptions and experience of current treatment in actinic keratosis

  • E. Stockfleth
  • , Ketty Peris
  • , C. Guillen
  • , R. Cerio
  • , N. Basset-Seguin
  • , P. Foley
  • , J. Sanches
  • , A. Culshaw
  • , S. Erntoft
  • , M. Lebwohl
  • Charité – Universitätsmedizin Berlin
  • Instituto Valenciano de Oncologia
  • Barts Health NHS Trust
  • Université Paris Cité
  • University of Melbourne
  • Universidade de São Paulo
  • Adelphi Group
  • LEO Pharma AS
  • Icahn School of Medicine at Mount Sinai

Research output: Contribution to journalArticle

Abstract

Topical therapy is important in the treatment of actinic keratosis (AK), a major risk factor for, and early development stage of, squamous cell carcinoma. Despite this, research addressing the limitations and challenges associated with topical field therapy in actinic keratosis is lacking.
Original languageEnglish
Pages (from-to)N/A-N/A
JournalJournal of the European Academy of Dermatology and Venereology
DOIs
Publication statusPublished - 2014

Keywords

  • actinic keratosis

Fingerprint

Dive into the research topics of 'Physician perceptions and experience of current treatment in actinic keratosis'. Together they form a unique fingerprint.

Cite this